Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]MNI-1054
- Development stage
- Discontinued
- Lead developer
- Invicro
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]MNI-1054 is a small molecule, enzyme-targeted radiopharmaceutical developed as a positron emission tomography (PET) imaging agent. It acts as a marker for lysine-specific histone demethylase 1A (KDM1A/LSD1), enabling the visualization and quantification of this enzyme in the brain. The compound is used primarily in research settings to assess KDM1A occupancy, particularly in studies evaluating the pharmacodynamics of KDM1A inhibitors such as TAK-418. Its mechanism involves enhancing PET imaging signals by binding specifically to LSD1/KDM1A, facilitating non-invasive measurement of target engagement in clinical trials[1][2][3][5].
02
Targets
KDM1A (LSD1)
Beyond the preview
Go deeper on [18F]MNI-1054.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]MNI-1054.